Rosiglitazone Decreases Plasma Levels of Osteoprotegerin in a Randomized Clinical Trial with Type 2 Diabetes Patients - Nybo, M; Preil, S R; Juhl, H F; Olesen, M; Yderstraede, K; Gram, J; Henriksen, J E; Rasmussen, L M (Basic Clin Pharmacol Toxicol, 2011)